Ireland’s Missing Pharma Engine: Why Indigenous SMEs Matter - Paul McCabe

In this episode, Patricia Grimes of Orion GXP Consulting discusses what it means to be inspection-ready as an everyday practice, not to appear perfect, but to manage risk, document issues, and protect patients. She highlights the importance of a strong quality culture, collaboration between QA and operations, working constructively with the HPRA, and using gap analyses to identify and address business-specific risks.Contact us at: [email protected] episode is sponsored by Molnlycke.

In this episode, Brendan McGrath shares his story of him being the first employee of WuXi Biologics in Ireland and how he helped turn an empty site into a 46,000 m² biologics facility in Dundalk. He shares the greenfield risk he took, building through COVID and Brexit with 1,800 workers on site, and where automation, predictive data and sustainability are taking pharma manufacturing next. Contact us at: [email protected] episode is sponsored by Molnlycke.

Executive Director of the ARC Hub* for Therapeutics, Araz Raoof, joins Pharma Conversations to unpack why Europe leads the world in scientific papers yet lags in new drug approvals, and how Ireland’s ARC Hub for Therapeutics is trying to change that. She explains the “valley of death” where academic breakthroughs often stall, the role of AI in modern drug discovery, why Ireland is a pharma manufacturing powerhouse but weak in indigenous biotech, and what ARC Hub offers to students and early‑career researchers. Araz also shares personal stories, from HIV drug development to her love of gardening, as metaphors for patience, integration, and impact in drug discovery.*The ARC Hub for Therapeutics is co-funded by the Government of Ireland and the European Union through the ERDF Southern, Eastern & Midland Regional Programme 2021-2027.Contact us at: [email protected] episode is sponsored by Molnlycke.

In this episode of Pharma Conversations, Paul McCabe, COO of APC/VLE unpacks the hidden world of Ireland’s indigenous biopharma SMEs, and why, despite a world-class multinational presence, the ecosystem is incomplete. He explores funding gaps, missing infrastructure, talent and entrepreneurial barriers, while sharing his own journey from big pharma to building an Irish-grown global player.Contact us at: [email protected] episode is sponsored by Kaye.

Sustainability in pharma isn’t a side project anymore – it’s fast becoming core operational excellence. In this episode of Pharma Conversations, we sit down with Michael Kilkelly (IBEC) to explore how Irish pharma is leading on decarbonisation, the real challenges behind scope 1–3 emissions, and practical ways to embed sustainability from the boardroom to the cleanroom. A must-listen for anyone serious about turning ESG into measurable results.Contact us at: [email protected] episode is sponsored by Kaye.

In this episode John Shabushnig, founder of Insight Pharma Consulting explains what visual inspection really means for injectable products, from manual methods to advanced automated systems. He tackles difficult-to-inspect products, visible particle risk, and common pitfalls in validating automation. John also shows how life-cycle thinking turns inspection data into real process and quality improvements.Contact us at: [email protected] episode is sponsored by Kaye.

In this episode of Pharma Conversations, Maria Ginnelly explains the impact of the EU GMP Annex 1 (section 5.5) on the sterilisation of indirect product-contact parts in sterile manufacturing. She explains why regulators now expect these parts to be treated as critical, why VHP alone is insufficient, and how legacy lines can use QRM, smoke studies, EM/PM, and enhanced gowning to build a defensible contamination control strategy. Maria also challenges equipment and wrapping vendors to rethink design for Grade A continuity, sharing practical, operator-focused ideas drawn from real-world experience.Contact us at: [email protected] episode is sponsored by Orion GXP Consulting.

In this episode, Charlie Maxwell of Orion GXP Consulting, breaks down what non‑EU pharma and biotech companies need to get right when launching in Europe, from choosing the right HQ location and operating model to deciding between building infrastructure and outsourcing to CDMOs, 3PLs and contract QPs. Charley explains why Europe is not one homogeneous market, how to avoid “tanking your pricing floor” through poor launch sequencing, and the crucial role of local quality, regulatory and distribution partners in making a European entry successful.Contact us at: [email protected] episode is sponsored by Orion GXP Consulting.

In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundational knowledge create real risk. Martin also shares practical examples of prompt engineering, governance, and “expert-in-the-loop” approaches that turn AI from a hype-driven threat into a powerful accelerator for quality and productivity.Contact us at: [email protected] episode is sponsored by Orion GXP Consulting.

In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process execution. Craig introduces his “4 Ps” model as a way to both understand and measure quality culture over time. He also explores why the quality function often gets blamed when things go wrong, and how clearer accountability across the organization can transform both outcomes and mindset.Contact us at: [email protected] episode is sponsored by STERIS.